AVROBIO Inc
NASDAQ:TECX

Watchlist Manager
AVROBIO Inc Logo
AVROBIO Inc
NASDAQ:TECX
Watchlist
Price: 22.32 USD -2.62% Market Closed
Market Cap: 416.7m USD

Net Margin
AVROBIO Inc

0%
Current
0%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-58.7m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
AVROBIO Inc
NASDAQ:TECX
416.7m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
129.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

AVROBIO Inc
Glance View

Market Cap
416.7m USD
Industry
Biotechnology

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.

TECX Intrinsic Value
7.54 USD
Overvaluation 66%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-58.7m
/
Revenue
0
What is the Net Margin of AVROBIO Inc?

Based on AVROBIO Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top